Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From Abivax SA

Abivax Advances Again On Funding Front

The French biotech has been making steady progress in raising the funds needed to advance obefazimod and this week has seen new equity backers Kreos, Claret and Heights come onboard.

Financing Gastrointestinal

How The Allure Of Abivax Kept Marc de Garidel From The Beach

Abivax has had its ups and downs but newly appointed CEO Marc de Garidel tells Scrip he is confident that the French group is onto a winner with its ulcerative colitis drug, obefazimod.

Leadership Inflammation

Abivax Banks €130m To Advance Obefazimod

The French biotech has attracted a raft of new US healthcare specialist backers in one of the biggest raises ever on the Euronext Paris but it will need millions more to complete the late-stage program for obefazimod.

Financing Inflammation

Abivax Secures Cash For Ulcerative Colitis Drug But Much More Needed

The French biotech is pleased to have raised nearly €50m considering the "currently very challenging financing environment," but it will need to find €150m more to complete last-stage trials of obefazimod in ulcerative colitis.

Financing Clinical Trials
See All

Company Information